Pulmonology

 Jacobs COPD Conferences provides a platform that helps authors to share their knowledge with a wider audience, and sustains a rapid process for submissions resulting in high quality publications. We further aim to contribute towards reducing the inequity in publications from low- and middle-income countries. Our audience is global and we intend to share research results in COPD from all parts of the world.

 Market Research onPulmonology

 The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reacha value of $15.6 billion by 2019. The drugs driving this growth include once-daily LABA/LAMA

fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium.

The opportunity in the U.S. and China asthma and COPD drugs market is slated to rise from a valuation of US$13.0 bn in 2015 to be worth US$18.7 bn by 2024. If these values hold true, the market is likely to expand at a modest CAGR of 4.1% therein.North America leads the global market for asthma &COPD drugs and devices. North America was followed by Europe in terms of market capitalization. Asia Pacific is expected to be the fastest regional market for asthma and COPD owing to the increased incidence of asthma & other respiratory diseases in industrial regions.The current asthma and COPD market is primarily driven by increasing patient population. It is also growing due to factors such as price erosion and expiry of patents of leading drug brands in the market. However, it is estimated that in the next five years, the global asthma and COPD drug market is expected to grow slowly and steadfast. The COPD segment was projected to be worth USD 10,593.2 million and is expected to reach USD 12,619.8 million in 2017.